Soligenix, Inc. (SNGX): Price and Financial Metrics


Soligenix, Inc. (SNGX): $1.12

-0.08 (-6.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SNGX POWR Grades


  • SNGX scores best on the Sentiment dimension, with a Sentiment rank ahead of 65.62% of US stocks.
  • SNGX's strongest trending metric is Momentum; it's been moving down over the last 113 days.
  • SNGX ranks lowest in Stability; there it ranks in the 4th percentile.

SNGX Stock Summary

  • With a year-over-year growth in debt of 11,208.14%, Soligenix Inc's debt growth rate surpasses 99.75% of about US stocks.
  • As for revenue growth, note that SNGX's revenue has grown -64.11% over the past 12 months; that beats the revenue growth of just 4.4% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SNGX comes in at -78.25% -- higher than that of merely 2.66% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Soligenix Inc, a group of peers worth examining would be BEDU, ACTG, ESCA, OPNT, and TEDU.
  • Visit SNGX's SEC page to see the company's official filings. To visit the company's web site, go to www.soligenix.com.

SNGX Price Target

For more insight on analysts targets of SNGX, see our SNGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.81 Average Broker Recommendation 1.83 (Hold)

SNGX Stock Price Chart Interactive Chart >

Price chart for SNGX

SNGX Price/Volume Stats

Current price $1.12 52-week high $2.99
Prev. close $1.20 52-week low $0.86
Day low $1.10 Volume 591,200
Day high $1.19 Avg. volume 2,695,851
50-day MA $1.20 Dividend yield N/A
200-day MA $1.64 Market Cap 44.89M

Soligenix, Inc. (SNGX) Company Bio


Soligenix, Inc. develops therapeutics and vaccines. The Company researches treatments for gastrointestinal Graft-versus-Host disease and cancer, and develops vaccines for military and civilian applications.


SNGX Latest News Stream


Event/Time News Detail
Loading, please wait...

SNGX Latest Social Stream


Loading social stream, please wait...

View Full SNGX Social Stream

Latest SNGX News From Around the Web

Below are the latest news stories about Soligenix Inc that investors may wish to consider to help them evaluate SNGX as an investment opportunity.

Soligenix soars 13% after securing PIP waiver for HyBryte in blood cancer in Europe

Soligenix (SNGX) jumps 13% premarket after receiving a Pediatric Investigation Plan ((PIP)) waiver from the EMA for HyBryte (SGX301 or hypericin), which has recently and successfully concluded a Phase 3 study for the treatment of early stage cutaneous T-cell lymphoma ((CTCL)). As part of the regulatory process for the registration of new medicines...

Seeking Alpha | June 10, 2021

Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received a Pediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for HyBryte™ (SGX301 or hypericin), which has recently and successfully concluded a Phase 3, pivotal clinical study for the treatment of early stage cutaneous T-cell ly

Yahoo | June 10, 2021

Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $865,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program.

Yahoo | June 9, 2021

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2021.

Yahoo | May 17, 2021

Village Farms International to Participate in BMO Capital Markets 16th Annual Farm to Market Conference

Village Farms International, Inc. ("Village Farms" or the "Company") (NASDAQ: VFF) (TSX: VFF) today announced that Michael DeGiglio, Chief Executive Officer, and Stephen Ruffini, Chief Financial Officer, will participate in a virtual "fireside chat" at the BMO Capital Markets 16th Annual Farm to Market Conference on Thursday, May 20, 2021, at 10:40 a.m. ET.

Yahoo | May 17, 2021

Read More 'SNGX' Stories Here

SNGX Price Returns

1-mo 7.69%
3-mo -34.88%
6-mo -19.42%
1-year -36.72%
3-year -13.85%
5-year -84.23%
YTD -12.50%
2020 -11.72%
2019 68.60%
2018 -61.26%
2017 -1.33%
2016 -80.09%

Continue Researching SNGX

Want to see what other sources are saying about Soligenix Inc's financials and stock price? Try the links below:

Soligenix Inc (SNGX) Stock Price | Nasdaq
Soligenix Inc (SNGX) Stock Quote, History and News - Yahoo Finance
Soligenix Inc (SNGX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9559 seconds.